AR127893A1 - CANCER THERAPY TARGETTING EGFR - Google Patents
CANCER THERAPY TARGETTING EGFRInfo
- Publication number
- AR127893A1 AR127893A1 ARP220103358A ARP220103358A AR127893A1 AR 127893 A1 AR127893 A1 AR 127893A1 AR P220103358 A ARP220103358 A AR P220103358A AR P220103358 A ARP220103358 A AR P220103358A AR 127893 A1 AR127893 A1 AR 127893A1
- Authority
- AR
- Argentina
- Prior art keywords
- egfr
- targetting
- cancer therapy
- component
- tipiracil
- Prior art date
Links
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- QQHMKNYGKVVGCZ-UHFFFAOYSA-N tipiracil Chemical compound N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 QQHMKNYGKVVGCZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002952 tipiracil Drugs 0.000 abstract 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 abstract 1
- 229960003962 trifluridine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
Una combinación que comprende (a) un componente de anticuerpos anti-EGFR que comprende uno o dos anticuerpos anti-EGFR o porciones de unión a antígeno de los mismos y (b) un componente de trifluridina / tipiracilo.A combination comprising (a) an anti-EGFR antibody component comprising one or two anti-EGFR antibodies or antigen-binding portions thereof and (b) a trifluridine/tipiracil component.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21306751 | 2021-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127893A1 true AR127893A1 (en) | 2024-03-06 |
Family
ID=80035092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220103358A AR127893A1 (en) | 2021-12-10 | 2022-12-07 | CANCER THERAPY TARGETTING EGFR |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR127893A1 (en) |
TW (1) | TW202339796A (en) |
WO (1) | WO2023105051A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE245631T1 (en) | 1995-03-29 | 2003-08-15 | Taiho Pharmaceutical Co Ltd | URACIL DERIVATIVES AND ANTITUMOR EFFECT ENHANCERS CONTAINING SAME AND ANTITUMOR AGENTS |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
ES2582386T3 (en) * | 2007-03-01 | 2016-09-12 | Symphogen A/S | Compositions of recombinant antibodies against epidermal growth factor receptor |
MX2013010444A (en) * | 2011-03-15 | 2014-03-21 | Merrimack Pharmaceuticals Inc | Overcoming resistance to erbb pathway inhibitors. |
PL3042669T3 (en) * | 2013-09-06 | 2023-06-26 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and antitumor effect enhancer |
EP3695013A1 (en) * | 2017-08-30 | 2020-08-19 | Symphogen A/S | Compositions and methods for treating cancer with anti-egfr antibodies |
-
2022
- 2022-12-07 AR ARP220103358A patent/AR127893A1/en unknown
- 2022-12-09 TW TW111147411A patent/TW202339796A/en unknown
- 2022-12-09 WO PCT/EP2022/085198 patent/WO2023105051A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202339796A (en) | 2023-10-16 |
WO2023105051A1 (en) | 2023-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020003071A1 (en) | Multispecific binding proteins and enhancements with them | |
EP3746119A4 (en) | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody | |
CL2020003223A1 (en) | Il-11 antibodies | |
CL2023002105A1 (en) | Antibody variable domains targeting cd33 and their uses | |
ECSP17005649A (en) | HUMANIZED ANTI-TAU ANTIBODIES | |
EA202092000A1 (en) | EGFR DIMERIZATION INHIBITORS AND THEIR USE | |
AR113224A1 (en) | ANTIBODY CONJUGATES INCLUDING A STING AGONIST | |
BR112018013995A2 (en) | oncolytic virus combination therapy and checkpoint inhibitor | |
ECSP20082648A (en) | ANTI-SIRPA ANTIBODIES AND METHODS OF USING THEM | |
EA202091964A1 (en) | COMBINED PRODUCT BASED ON Bcl-2 INHIBITOR AND MDM2 INHIBITOR AND ITS APPLICATION IN THE PREVENTION AND / OR TREATMENT OF DISEASES | |
BR112021015036A2 (en) | Cancer treatment with ror1 antibody immunoconjugates | |
EA202091810A1 (en) | ANTIBODIES TO B7-H4 AND METHODS OF THEIR APPLICATION | |
CL2023000741A1 (en) | Anti-nectin-4 antibody, conjugate that includes it and application thereof. | |
CO2022004743A2 (en) | Antibodies directed to flt3 and use thereof | |
BR112019023909A2 (en) | method for treating a patient with ovarian cancer, peritoneal cancer or fallopian tube cancer. | |
CO2021008665A2 (en) | Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies | |
CL2020003391A1 (en) | Anti-steap1 antigen binding protein | |
AR127893A1 (en) | CANCER THERAPY TARGETTING EGFR | |
CY1124183T1 (en) | ANTI-SEZ6 DRUG CONJUGATES AND METHODS OF USE | |
AU2019379261A8 (en) | Pharmaceutical combination of anti-CEACAM6 and either anti-PD-1 or anti-PD-l1 antibodies for the treatment of cancer | |
BR112022011280A2 (en) | ANTI-CD5 ANTIBODY FOR THE TREATMENT OF NEUROMYELITIS OPTIC SPECTRUM DYSFUNCTION | |
MX2020004074A (en) | Combination product for the treatment of cancer. | |
MX2021012130A (en) | Combinations of transcription inhibitors and immune checkpoint inhibitors for treatment of disease. | |
AR119296A1 (en) | SARS COV-2 ANTI-PROTEIN S GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | |
EA202193113A1 (en) | KRAS INHIBITOR DOSE FOR CANCER TREATMENT |